Aeterna Zentaris Slides on Perifosine Miss in Myeloma
By Staff Reports
Monday, March 11, 2013
Shares of Aeterna Zentaris dropped 22.5 percent Monday after a data safety monitoring board (DSMB) said it was unlikely a Phase III study testing PI3/Akt inhibitor perifosine in multiple myeloma would hit its endpoints.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.